23.04.2013 09:01
Bewerten
 (0)

PRESS RELEASE: SYGNIS granted US patent for QUALIPHI(R), the Next Generation DNA amplification tool

SYGNIS Pharma / SYGNIS granted US patent for QUALIPHI(R), the Next Generation DNA amplification tool . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

New patent opens SYGNIS and QUALIPHI(R) in a leading position in a EUR70 million global market.

-- QUALIPHI(R) is a DNA polymerase which has demonstrated the potential to improve complete DNA amplification from minimal concentrations

-- Polymerase proteins are essential in the research and analysis or modification of DNA

-- QUALIPHI(R) reduces reaction time to 2 hours

-- Currently, the global DNA amplification market is estimated at EUR70 million, with the US the largest market.

Madrid/Heidelberg, 23 April 2013 - The biotech company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) has been granted a patent by the USPTO (US patent and Trademark office) for its flagship product, QUALIPHI(R) the polymerase for complete DNA amplification. Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are a basic need for research involving the analysis and modification of DNA.

QUALIPHI(R) is an upgraded version of the Phi 29 DNA polymerase used in isothermal amplification which provides enhanced properties compared to similar polymerase proteins on the market. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, and many other applications.

"Certainly, the need for amplification of nucleic acids from minimal concentrations as present in single cell applications will be a critical issue in the coming era of personalised medicine and NGS. We expect QUALIPHI(R) to become an essential tool for the DNA amplification needed in these markets", said SYGNIS' CEO, Pilar de la Huerta.

With the significant growth in the field of DNA amplifications used in sequencing and personalised medicine, the market of whole genome amplification with polymerase proteins is expected to grow at over 20% per annum over the next few years. Current estimates indicate that the size of the global isothermal DNA market alone is approximately EUR70 million, with the US as the leading market for QUALIPHI(R) .

In 2012, SYGNIS granted an exclusive global licence to QIAGEN, including sublicensing rights, for the commercialization of QUALIPHI(R) in the DNA amplification market. QIAGEN is a global leader in sample and assay technologies in research and molecular diagnostics.

About SYGNIS Pharma AG: www.sygnis.de

After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QUALIPHI(R) , and is currently developing other products in the field of Next Generation Sequencing.

For further information:

Pilar de la Huerta

CEO/CFO of SYGNIS Pharma AG

,+34 902 02 69 31 / 609 47 29 34 / 654 41 01 11

# # # Disclaimer:

Some statements included in this press release, relating neither to proven financial results nor to other historical data, should be viewed as forward-looking, i.e. not definitive. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature, they are subject to known and unknown risks, as well as to aspects beyond human control, and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. # # #

Press release (PDF): http://hugin.info/150277/R/1695126/557691.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: SYGNIS Pharma via Thomson Reuters ONE

HUG#1695126

--- End of Message ---

SYGNIS Pharma

Im Neuenheimer Feld 515 Heidelberg Germany

http://www.sygnis.de/index_eng.html (END) Dow Jones Newswires

   April 23, 2013 02:31 ET (06:31 GMT)- - 02 31 AM EDT 04-23-13

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Familienunternehmen: Rendite und Sicherheit!

Zwischen Eigentümern und Managern eines Unternehmens besteht häufig ein Interessenskonflikt hinsichtlich kurz- und langfristiger Ziele. Familien- und eigentümergeführte Unternehmen haben solche Konflikte meist nicht. Für Aktionäre sind solche Unternehmen daher meist eine lohnenswerte Investitionsmöglichkeit. Im neuen Anlegermagazin lesen Sie, welche drei Familienunternehmen einen näheren Blick wert sind.
Anlegermagazin kostenlos erhalten

Heute im Fokus

DAX legt zu -- Dow fester -- Großaktionäre drängen STADA-Führung zu Okay für Übernahme -- RATIONAL und Rheinmetall erhöhen Dividende -- freenet, CTS, United Internet, Commerzbank im Fokus

CS erwägt angeblich Kapitalerhöhung statt IPO der Schweiz-Tochter. Chinesen sichern sich größeres Stück an der Deutschen Bank. Schweizerische Notenbank kauft weniger Devisen zur Schwächung des Franken. Mega-Dividende: Die reichste Frau Deutschlands wird noch reicher. Commerzbank rechnet mit Abwertung des Britischen Pfunds.

Umfrage

Welche Risikopräferenz haben Sie beim Kauf eines Wertpapiers? Welcher der drei folgenden Risikoklassen würden Sie sich persönlich zuordnen?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
Volkswagen AG Vz. (VW AG)766403
CommerzbankCBK100
Nordex AGA0D655
Apple Inc.865985
Allianz840400
SAP SE716460
E.ON SEENAG99
Deutsche Telekom AG555750
MediGene AGA1X3W0
BMW AG519000
BASFBASF11
Deutsche Lufthansa AG823212
Volkswagen St. (VW)766400